誠如該公告所披露，載有（其中包括）續訂之銷售框架性協議及續訂之採購框架性協議 及其項下擬進行之持續關連交易之建議年度上限之詳情、獨立董事委員會函件及獨立財 務顧問致獨立董事委員會及獨立股東之意見，連同召開本公司股東特別大會之通告的通 函（「通函」）將適時寄發予股東。 由於本公司需要額外時間完成通函所載資料及安排刊發通函，通函的寄發日期預期將延 遲至二零二五年十一月三十日或之前。 承董事會命 北京同仁堂科技發展股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代號：1666) 延遲寄發通函 茲提述北京同仁堂科技發展股份有限公司（「本公司」）日期為二零二五年九月二十九 日之公告（「該公告」），內容有關續訂銷售框架性協議及採購框架性協議項下擬進行 之持續關連交易。除另行界定外，本公告所用詞彙與該公告所界定者具有相同涵義。 二零二五年十月二十二日 截至本公告日期，董事會包括執行董事張毅先生、張春 ...

Core Viewpoint - The Beijing International Intangible Cultural Heritage Week showcased traditional Chinese medicine practices, particularly the handmade production of Tong Ren Tang's An Gong Niu Huang Wan, highlighting the importance of cultural heritage in modern health practices [1][11]. Group 1: Event Highlights - The event featured a live demonstration of the traditional production techniques of An Gong Niu Huang Wan by Kong Lingjun, a master craftsman, allowing attendees to experience the charm of traditional Chinese medicine [1][11]. - The exhibition included a variety of Tong Ren Tang's major traditional Chinese medicine products, such as Liu Wei Di Huang Wan and Qian Bei Pi Pa Tang, providing visitors with comprehensive health information for the autumn season [9]. Group 2: Audience Engagement - Attendees expressed curiosity and eagerness to participate in the hands-on experience of making medicinal pills, with many finding the process more challenging than expected [5][7]. - Children showed particular interest in the pill-making process, with parents supporting their engagement in traditional culture through hands-on learning experiences [7]. Group 3: Craftsmanship and Training - Kong Lingjun emphasized the importance of skill and precision in the pill-making process, noting that mastering the technique requires at least three years of training to meet GMP standards [11]. - The company focuses on the transmission and development of traditional craftsmanship, ensuring that the skills are passed down to future generations through practical training [11].

Core Insights - The company has successfully completed the medical material reserve task assigned by the Beijing Municipal Drug Administration, reinforcing the logistics support for regional public health emergency guarantees [1][4] - The company is a significant producer of traditional Chinese medicine under the Tongrentang Group, with a portfolio of nearly 200 products, including popular items like Ganmao Qingre Granules and Banlan Gen Granules [1][4] - The company has established a modern warehouse capable of storing 1.31 million units of traditional Chinese medicine products and has a complete intelligent logistics distribution system [1] Group 1 - The company has been recognized as a city-level medical material reserve unit, which tests its ability to fulfill social responsibilities and supply tasks [4] - A total of 460,000 boxes of five product specifications, including Ganmao Qingre Granules and Banlan Gen Granules, have been included in the reserve list [4] - The quality and safety of the reserve materials are crucial for effective emergency support, leading the company to implement a special reserve management and emergency allocation plan [4][6] Group 2 - The logistics distribution center has enhanced protective measures and established a designated area for city-level medical reserves, ensuring compliance and traceability of stored materials [4][6] - The center conducts regular emergency allocation drills every two months to improve operational accuracy and efficiency, ensuring timely delivery during emergencies [6] - The company achieved its "six zero" goals during the task period, including zero quality issues and zero delays in emergency responses [8] Group 3 - The company plans to further develop its system, personnel, and operational processes to enhance the management of medical material reserves and extend these practices to the overall drug management process [8] - The aim is to improve management precision and contribute significantly to public medication safety and regional public health security [8]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全 部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1666） 建議續訂持續關連交易 銷售框架性協議及採購框架性協議 董事會謹此宣佈，由於本公司與集團公司訂立之銷售框架性協議及採購框架性協議 均將於二零二五年十二月三十一日到期，故訂約各方於二零二五年九月二十九日續 訂該等協議，協議期限均自二零二六年一月一日起至二零二八年十二月三十一日 止，為期三年，並分別訂立上述協議項下截至二零二八年十二月三十一日止三個年 度之各自擬進行之持續關連交易年度上限。 於本公告日期，集團公司乃本公司之最終控股股東，故根據香港上市規則為本公司 之關連人士。因此，根據香港上市規則第14A章，續訂之銷售框架性協議及續訂之 採購框架性協議項下擬進行之交易均構成本公司之持續關連交易。 由於續訂之銷售框架性協議及續訂之採購框架性協議項下擬進行之持續關連交易預 期年度上限之一項或多項適用百分比率分別均高於5%，因此，續訂之銷售框架性協 議及續訂之採購框架性協議及其項下擬進行之持 ...

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. showcased traditional Chinese medicine at the 2025 China Open Tennis Tournament, blending ancient practices with modern health concepts to attract a younger audience [1][12]. Group 1: Product Showcase - The exhibition featured a variety of traditional Chinese medicine products, including Shengmai Drink, Liuwei Dihuang Wan, and Jingshi Niuhuang Jiedu Pian, highlighting the company's strong foundation in traditional medicine [3]. - A range of health products was also presented, such as health drinks, skincare masks, and hair care products, aligning with the health-oriented philosophy of the event [5]. Group 2: Engagement with Athletes - Notable tennis player Sorana Cirstea participated in a hands-on experience of making herbal sachets, demonstrating the interactive approach of the exhibition [8][10]. - The company aims to enhance global recognition of traditional Chinese medicine through athlete involvement and innovative presentations [12]. Group 3: Scent Products - The company introduced its "Bencao Zhi Yue" series and other aromatic products at the player’s banquet, which became a popular attraction among attendees [13][16]. - The scent products are developed based on the concept of "medicinal fragrance," with nearly 140 products available, focusing on benefits like sleep aid and relaxation [18]. Group 4: Market Expansion - The products were also made available in 16 authorized cultural and creative stores during the event, expanding the reach of Tongrentang's offerings to a broader audience [21].

Core Points - Tong Ren Tang Technologies (01666.HK) announced that its subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1][2] Group 1 - The registered product is "Tong Ren Tang An Gong Niu Huang Wan" [2] - The license holder is Beijing Tong Ren Tang Guo Yao Co., Ltd., located at 14/F, 1405-1409, Convention Plaza, 1 Harbour Road, Wan Chai, Hong Kong [2] - The registration number is CAM N0004IT-25, and the license is valid until September 11, 2028 [2] Group 2 - The acquisition of the license will help enrich the distribution channels of the group's key products and facilitate market expansion [2] - The impact of this license on the group's production operations and performance is not expected to be significant [2] - Sales of the medicine may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [2]

Core Insights - Tong Ren Tang Technology (01666.HK) announced that its subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1][2] Group 1 - The drug "Tong Ren Tang An Gong Niu Huang Wan" is now authorized for sale in Cambodia, which will enhance the distribution channels for the company's key products and support market expansion [1][2] - The registration number for the license is CAM N0004IT-25, and it is valid until September 11, 2028 [2] - The acquisition of this license is not expected to have a significant impact on the company's production operations and performance in the short term [2] Group 2 - The sales of the drug may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [2][3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 自願公告 獲發傳統藥品註冊許可證 1 二、 藥品的其他相關情況 「同仁堂安宮牛黃丸」應遵照持證的中醫師的指導下使用。另外，早前柬埔寨衛生部亦 已頒發「同仁堂安宮牛黃丸」進口許可證。 本公告由北京同仁堂科技發展股份有限公司（「本公司」，連同本公司之附屬公司，「本 集團」）之董事會（「董事會」）自願作出，旨在使本公司股東及潛在投資者了解本集 團之最新業務發展。 董事會欣然宣佈，本公司之附屬公司北京同仁堂國藥有限公司（「同仁堂國藥」）於近 日收到柬埔寨王國（「柬埔寨」）衛生部藥品與食品司頒發的《傳統藥品註冊許可證》 （「許可證」），准許將同仁堂國藥的「同仁堂安宮牛黃丸」在柬埔寨出售，相關情況 公告如下： 一、 藥品基本狀況 藥品名稱：同仁堂安宮牛黃丸 許可證持有人名稱及地址：北京同仁堂國藥有限公司，中國香港灣仔港灣道 1 號會展廣 場辦公大樓 ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]